TY - JOUR
T1 - Study on Prescription Technology of Sofosbuvir/Ledipasvir Tablet
AU - Gu , Shihai
AU - Hou , Chunyuan
JO - Communications in Computational Chemistry
VL - 3
SP - 86
EP - 95
PY - 2018
DA - 2018/10
SN - 5
DO - http://doi.org/10.4208/cicc.2017.v5.n3.4 
UR - https://global-sci.org/intro/article_detail/cicc/12747.html
KW - Harvoni$^{\rm TM}$, Prescription Technology, Sofosbuvir.
AB - <p style="text-align: justify;">Clone the Harvoni<span style="font-size: 13.3333px;">$^{\rm TM}$</span>(Sofosbuvir/Ledipasvir) tablet manufactured by Gilead
Sciences, Inc. and screen out the best formula of prescription, to make the pesticide
effect of prepared tablet was equal to the original tablet. Methods: Based on the
prescription of Harvoni<sup>TM</sup> manufactured by Gilead Sciences, Inc., the compatibility test
of the excipient with the active ingredient was carried out. The stability of self-made
samples and reference preparations were investigated, which includes high
temperature, high humidity and light conditions. According to the above test, the most
reasonable prescription process was chosen. Results: The determined prescription
process contained sofosbuvir (400mg), ledipasvir (90mg), copovidone (97.5mg),
croscarmellose sodium (50mg), microcrystalline cellulose (115mg), lactose
monohydrate (230mg), magnesium stearate (7.5mg), gum arabic(10mg), opadry film
coating powder, and purified water. Conclusion: The determined prescription process
was stable and the pesticide effect of prepared tablet was equal to the original tablet, so
the prescription design was reasonable.</p>